| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
 |
1. Approach and Goals |
 TOP 1. Approach and Goals 2. Process |
|---|
During the Forum subgroups focused on clinical, epidemiologic, and other scientific research issues important to filariasis, public health and the GPELF. These issues included pathogenesis, disease management, infection in children, drug use, drug development, diagnostic tools, strategies for employing these tools, modeling to define critical epidemiologic endpoints, vector biology, and others.
The results of these Forum meetings paint a detailed picture of the filariasis research horizon today. Useful in its own right for researchers and funding agencies, it should also serve as a firm scientific base for the subsequent development by a WHO/TDR Scientific Working Group, of an agreed Strategic Plan for Research to Support the GPELF.
|
2. Process |
|
TOP1. Approach and Goals2. Process |
|---|
Rather than seeking a single donor to underwrite the costs of the Forum, it was decided to request smaller sums ($5,000 to $20,000) from several different organizations both to decrease the burden on these organizations and to broaden the Forum’s support base. Indeed, nine organizations (three commercial, four non-governmental, and two governmental agencies) contributed to support this meeting; these were the Ellison Medical Foundation, The Geneva Foundation for Tropical Diseases, GlaxoSmithKline, Health and Development International, Merck & Company, Inc., New England Biolabs, The U.K. Department for International Development, The U.S. National Institute of Allergy and Infectious Diseases, and the Wellcome Trust. In addition, of the 66 participants, 44 investigators from 26 different organizations supported their own costs for meeting participation.
Participants Sixty-six senior scientists and experts in filariasis from 21 different countries participated in the LF Forum. Another 24 invited participants from 11 countries (all but two represented by other attendees) were unable to attend but agreed to have an input into this process through review of the draft documents. An additional list of nine potential invitees from five different countries (only one not otherwise represented) was developed, but not acted upon because of budgetary constraints.
Organization Initially an organizing committee representing six institutions (including WHO/CEE and WHO/TDR) identified 10 subtopics covering the range of scientific issues addressable at this Forum. These were the following: 1) Chemotherapy, 2) LF Infection and Drug trials, 3) LF Disease and Treatment Trials, 4) Pathogenesis, 5) Diagnostics, 6) Epidemiology and Parasite Biology, 7) Program Implementation, 8) Program Monitoring & Evaluation, 9) Protective Immunity, and 10) Vector Biology.
Prior to the Forum, each participant was asked to select two of these subtopics on which to focus in Working Groups at the Forum. Once the Groups were constituted, a chairperson was designated who then contacted the Working Group members prior to the Forum itself.
During the two-day Forum, the 10 working groups (6–15 individuals per group) met twice in five parallel sessions to determine the most important researchable questions in their topic area and what the priority of these questions should be with respect not only to the GPELF, but to other aspects of science and public health as well. Conclusions from all 10 working groups were reviewed in plenary and subsequently distributed to all forum participants.
Final Report Summaries of the subtopics and the conclusions reached by the Working Groups were prepared by the Group chairpersons and assembled into the first draft of a comprehensive document that was sent for review by all meeting participants and invitees. The document was then redrafted into this present final report.
This article has been cited by other articles:
|
|
 |
|
  F. O. ter Kuile, A. M. van Eijk, and S. J. Filler Effect of Sulfadoxine-Pyrimethamine Resistance on the Efficacy of Intermittent Preventive Therapy for Malaria Control During Pregnancy: A Systematic Review JAMA, June 20, 2007; 297(23): 2603 - 2616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. BROUQUI, J. M. ROLAIN, C. FOUCAULT, and D. RAOULT Q FEVER AND PLASMODIUM FALCIPARUM MALARIA CO-INFECTION IN A PATIENT RETURNING FROM THE COMOROS ARCHIPELAGO Am J Trop Med Hyg, December 1, 2005; 73(6): 1028 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. FRIEDMAN, A. M. KWENA, L. B. MIREL, S. K. KARIUKI, D. J. TERLOUW, P. A. PHILLIPS-HOWARD, W. A. HAWLEY, B. L. NAHLEN, Y. P. SHI, and F. O. T. KUILE MALARIA AND NUTRITIONAL STATUS AMONG PRE-SCHOOL CHILDREN: RESULTS FROM CROSS-SECTIONAL SURVEYS IN WESTERN KENYA Am J Trop Med Hyg, October 1, 2005; 73(4): 698 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. NYUNT, J. PISCIOTTA, A. B. FELDMAN, P. THUMA, P. F. SCHOLL, P. A. DEMIREV, J. S. LIN, L. SHI, N. KUMAR, and D. J. SULLIVAN JR. DETECTION OF PLASMODIUM FALCIPARUM IN PREGNANCY BY LASER DESORPTION MASS SPECTROMETRY Am J Trop Med Hyg, September 1, 2005; 73(3): 485 - 490. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
